Singapore markets open in 2 minutes

23andMe Holding Co. (ME)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.5003-0.0019 (-0.38%)
At close: 04:00PM EDT
0.5015 +0.00 (+0.24%)
After hours: 07:37PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.5022
Open0.5050
Bid0.4982 x 900
Ask0.5021 x 2000
Day's range0.4931 - 0.5288
52-week range0.3500 - 2.2100
Volume3,076,798
Avg. volume7,560,475
Market cap241.603M
Beta (5Y monthly)1.28
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Insider Monkey

    7 Best Sites Like Ancestry.com to Research Your Family History

    In this article, we take a look at 7 best sites like Ancestry.com to research your family history. If you would like to skip our detailed analysis of the genealogy industry, you can directly go to 3 Best Sites Like Ancestry.com to Research Your Family History. The Genealogy Industry Genealogy is the study of families, […]

  • Barrons.com

    23andMe CEO Anne Wojcicki Says She’s Weighing Buyout Bid

    In what looks like a potentially downbeat ending to 23andMe journey as a public company, founder and CEO Anne Wojcicki has offered to take the DNA testing business private. Wojcicki, who controls more than 20% of 23andMe’s stock, with about 49% voting control, told the company that she is considering making an offer to buy the shares she doesn’t already own. Neither Wojcicki nor the company have commented on what she might be willing to pay, but investors appear skeptical that it will come at a premium price.

  • Reuters

    23andMe CEO Wojcicki considering taking firm private, filing shows

    Last week, Wojcicki notified members of the board's special committee that she is considering a potential go-private transaction for 23andMe and indicated that she would begin speaking to partners and financing sources. 23andMe declined to comment on the filing and Wojcicki did not immediately respond to a Reuters' request for comment. 23andMe, best known for its saliva-based test kits that offer users a glimpse into their genetic ancestry went public in 2021 through a blank-check firm, backed by Virgin Group founder Richard Branson, in a deal that valued the merged entity at $3.5 billion.